Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George M Simpson

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Schizophrenia Research|November 25, 2004
Plasma clozapine concentration coefficients of variation in a long-term studyFrancisco J Diaz, Jose de Leon, Richard C Josiassen, et al.
The American Journal of Psychiatry|October 7, 2004
Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorderGeorge M Simpson, Ira D Glick, Peter J Weiden, et al.
International Clinical Psychopharmacology|June 12, 2008
Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidoneCarla M Canuso, Eriene A Youssef, Cynthia A Bossie, et al.
The Journal of Clinical Psychiatry|May 14, 2005
An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depressionGeorge M Simpson, Adel El Sheshai, Nasser Loza, et al.
Journal of Clinical Psychopharmacology|November 13, 2004
Haloperidol half-life after chronic dosingJose de Leon, Francisco J Diaz, Peter Wedlund, et al.
Schizophrenia Research|April 6, 2004
Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophreniaPhilip D Harvey, Herbert Meltzer, George M Simpson, et al.
Journal of Clinical Psychopharmacology|August 16, 2003
Serum antimuscarinic activity during clozapine treatmentJose de Leon, Aruby Odom-White, Richard C Josiassen, et al.
The Journal of Clinical Psychiatry|September 13, 2006
A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorderGeorge M Simpson, Ramy A Mahmoud, Robert A Lasser, et al.
Annals of General Psychiatry|January 31, 2007
Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing intervalGeorges M Gharabawi, Natalie C Gearhart, Robert A Lasser, et al.
Schizophrenia Bulletin|August 12, 2003
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol developmentT Scott Stroup, Joseph P McEvoy, Marvin S Swartz, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Schizophrenia Research|November 25, 2004
Plasma clozapine concentration coefficients of variation in a long-term studyFrancisco J Diaz, Jose de Leon, Richard C Josiassen, et al.
The American Journal of Psychiatry|October 7, 2004
Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorderGeorge M Simpson, Ira D Glick, Peter J Weiden, et al.
International Clinical Psychopharmacology|June 12, 2008
Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidoneCarla M Canuso, Eriene A Youssef, Cynthia A Bossie, et al.
The Journal of Clinical Psychiatry|May 14, 2005
An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depressionGeorge M Simpson, Adel El Sheshai, Nasser Loza, et al.
Journal of Clinical Psychopharmacology|November 13, 2004
Haloperidol half-life after chronic dosingJose de Leon, Francisco J Diaz, Peter Wedlund, et al.
Schizophrenia Research|April 6, 2004
Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophreniaPhilip D Harvey, Herbert Meltzer, George M Simpson, et al.
Journal of Clinical Psychopharmacology|August 16, 2003
Serum antimuscarinic activity during clozapine treatmentJose de Leon, Aruby Odom-White, Richard C Josiassen, et al.
The Journal of Clinical Psychiatry|September 13, 2006
A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorderGeorge M Simpson, Ramy A Mahmoud, Robert A Lasser, et al.
Annals of General Psychiatry|January 31, 2007
Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing intervalGeorges M Gharabawi, Natalie C Gearhart, Robert A Lasser, et al.
Schizophrenia Bulletin|August 12, 2003
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol developmentT Scott Stroup, Joseph P McEvoy, Marvin S Swartz, et al.
Pageof 4